Design Therapeutics, Inc. financial data

Symbol
DSGN on Nasdaq
Location
Carlsbad, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2487% % -30%
Debt-to-equity 5% % 29%
Return On Equity -31% % -70%
Return On Assets -29% % -68%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56,963,757 shares 0.6%
Common Stock, Shares, Outstanding 56,963,757 shares 0.6%
Entity Public Float $112,536,269 USD -31%
Common Stock, Value, Issued $6,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 56,950,999 shares 0.58%
Weighted Average Number of Shares Outstanding, Diluted 56,950,999 shares 0.58%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Research and Development Expense $57,861,000 USD 34%
General and Administrative Expense $20,131,000 USD 14%
Operating Income (Loss) $77,992,000 USD -28%
Net Income (Loss) Attributable to Parent $67,446,000 USD -41%
Earnings Per Share, Basic -1 USD/shares -42%
Earnings Per Share, Diluted -1 USD/shares -42%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $15,088,000 USD -50%
Marketable Securities, Current $190,882,000 USD -15%
Cash, Cash Equivalents, and Short-term Investments $206,000,000 USD -19%
Assets, Current $209,029,000 USD -19%
Property, Plant and Equipment, Net $1,104,000 USD -29%
Operating Lease, Right-of-Use Asset $1,637,000 USD -32%
Assets $211,770,000 USD -19%
Accounts Payable, Current $1,913,000 USD 30%
Employee-related Liabilities, Current $3,466,000 USD 16%
Accrued Liabilities, Current $9,260,000 USD 55%
Liabilities, Current $11,173,000 USD 50%
Operating Lease, Liability, Noncurrent $877,000 USD -50%
Liabilities $12,050,000 USD 31%
Accumulated Other Comprehensive Income (Loss), Net of Tax $358,000 USD -61%
Retained Earnings (Accumulated Deficit) $281,009,000 USD -32%
Stockholders' Equity Attributable to Parent $199,720,000 USD -21%
Liabilities and Equity $211,770,000 USD -19%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $16,789,000 USD -35%
Net Cash Provided by (Used in) Financing Activities $23,000 USD 15%
Net Cash Provided by (Used in) Investing Activities $7,870,000 USD -62%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 56,963,757 shares 0.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $8,896,000 USD -209%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $15,088,000 USD -50%
Deferred Tax Assets, Valuation Allowance $53,143,000 USD 25%
Deferred Tax Assets, Gross $53,979,000 USD 24%
Operating Lease, Liability $1,743,000 USD -31%
Depreciation $159,000 USD 11%
Payments to Acquire Property, Plant, and Equipment $72,000 USD -63%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $68,002,000 USD -49%
Lessee, Operating Lease, Liability, to be Paid $1,876,000 USD -33%
Property, Plant and Equipment, Gross $3,212,000 USD 4.8%
Operating Lease, Liability, Current $866,000 USD 11%
Lessee, Operating Lease, Liability, to be Paid, Year Two $663,000 USD -32%
Lessee, Operating Lease, Liability, to be Paid, Year One $973,000 USD 3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $133,000 USD -54%
Lessee, Operating Lease, Liability, to be Paid, Year Three $663,000 USD -32%
Deferred Tax Assets, Operating Loss Carryforwards $18,885,000 USD 25%
Unrecognized Tax Benefits $2,289,000 USD 27%
Deferred Tax Assets, Net of Valuation Allowance $836,000 USD -14%
Share-based Payment Arrangement, Expense $14,585,000 USD 18%